Brand-name<unk> . Bottle of<unk>  20 mg tablets.<unk> , like other proton pump inhibitors such as omeprazole, is used for the purposes of gastric acid suppression. This effect is beneficial for the treatment and prevention of conditions in which gastric acid directly worsens symptoms, such as duodenal and gastric ulcers. In the setting of gastroesophageal reflux disease (GERD), whose pathophysiology is characterized by prolonged exposure to gastric acid in the esophagus (often due to changes in stomach and/or esophagus anatomy, such as those induced by abdominal obesity), acid suppression can provide symptomatic relief. Acid suppression is also useful when gastric production of acid is increased, including conditions with excess gastric acid secretion (hypersecretory conditions) like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.<unk>  is also useful alongside antibiotic therapy for the treatment of the pathogen Helicobacter pylori, which otherwise thrives in acidic environments. Notably, H. pylori eradication with antibiotics and<unk>  was also shown to prevent development of second gastric cancer in a randomized trial in high-risk South Korean patients with early stomach cancer treated by endoscopy. Thus,<unk>  is US Food and Drug Administration (FDA) approved for the treatment of symptomatic GERD in adolescents and adults, healing duodenal ulcers in adults, eradication of Helicobacter pylori, and pathologic hypersecretory conditions. Available forms<unk>  is available in 10 and 20 mg, delayed-release tablets (pictured below).<unk> -based products, like other proton pump inhibitor products, have to be formulated in delayed-release tablets to protect the active medication from being degraded by the acid of the stomach before being absorbed. Specific populations Pediatrics<unk> 's only pediatric indication is for the treatment of symptomatic GERD in adolescents (12 years-old and up). Pregnancy Studies using animals models to investigate the likelihood for<unk>  to cause harm to fetuses have not yet shown evidence of harm, though avoidance of<unk>  during pregnancy (especially during the critical development period of the first trimester) is considered to be the safest possible route until human studies clarify the exact risk. Lactation It is expected that<unk>  will be secreted into human breast milk, though the clinical impact of this is still unknown. Avoiding<unk>  during breastfeeding confers to lowest possible risk. Geriatrics Advanced age does not appear to clinically impact<unk> 's metabolism. However, elevations in the maximum plasma concentration and the total drug exposure (area under the curve, AUC) have occurred. Japanese ancestry In a study on<unk> 's pharmacokinetics, the AUC was elevated by approximately 50–60% in men of Japanese ancestry compared to men in the United States. See the pharmacogenetics section below for a pharmacogenetic explanation of these findings. Kidney or liver problems In people that have kidney or liver problems, these problems do not appear to affect<unk> 's metabolism in a clinically meaningful way. This includes individuals on dialysis for kidney problems. Severe liver problems like cirrhosis of the liver do affect<unk> 's elimination half-life, but not to a degree of dangerous accumulation. In a review of patients taking<unk>  while having end-stage kidney disease and mild-to-moderate severity, chronic compensated cirrhosis of the liver, the alteration in<unk> 's metabolism was not clinically meaningful.
Rabeprazole
Esomeprazole
Lansoprazole
Omeprazole
Dexlansoprazole
Tenatoprazole
Pantoprazole
Cimetidine